NCT00624676 is a NA clinical trial of Lipo Hydroxy Acid in Acne Vulgaris, sponsored by Cosmetique Active International.

Who is sponsoring NCT00624676?

NCT00624676 is sponsored by Cosmetique Active International.

What drugs are being tested in NCT00624676?

Interventions in NCT00624676: Lipo Hydroxy Acid, 5% benzoyl peroxide gel.

What condition does NCT00624676 study?

NCT00624676 studies Acne Vulgaris.

Is NCT00624676 still recruiting?

NCT00624676 is currently completed. Last updated 18 September 2011.

Last reviewed 2011-09-18 · How we verify

NCT00624676

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Randomized Study Comparing the Efficacy and Tolerance of a Lipophilic Hydroxy Acid Derivative of Salicylic Acid and 5% Benzoyl Peroxide in the Treatment of Facial Acne Vulgaris

Completed NA Last updated 18 September 2011

What this trial tests

NA trial testing Lipo Hydroxy Acid in Acne Vulgaris in 80 participants. Completed in 1 August 2006.

Timeline

1 January 2006

Primary endpoint
1 August 2006

1 August 2006

Quick facts

Lead sponsor	Cosmetique Active International
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	80
Start date	1 January 2006
Primary completion	1 August 2006
Estimated completion	1 August 2006
Sites	2 locations across Canada

Drugs / interventions tested

Lipo Hydroxy Acid — full drug profile →
5% benzoyl peroxide gel

Conditions studied

Acne Vulgaris — all drugs for Acne Vulgaris →

Sponsor

Cosmetique Active International — full company profile →

Who can join

18 and older, any sex, with Acne Vulgaris. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Reduction in inflammatory lesions
Time frame: Days 28, 56 and 87

Sponsor's own description

Acne vulgaris is a frequent inflammatory skin condition involving the pilosebaceous unit and affecting more than 80% of teenagers. Mild to moderate acne vulgaris is usually treated with topical agents such as benzoyl peroxide, retinoids and antibiotics. These treatments can be associated with local tolerance problems and/or antibiotic resistance. Salicylic acid has been shown to be an effective treatment for acne. LHA is a lipophilic hydroxy acid derivative of salicylic acid that has comedolytic and antibacterial properties. The objective of this trial was to compare the efficacy and tolerance of a cream formulation containing 0.3% LHA (LHA formulation) to a 5% benzoyl peroxide gel.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Topical benzoyl peroxide for acne.
Yang Z, Zhang Y, Lazic Mosler E, Hu J, et al · · 2020 · cited 29× · PMID 32175593 · DOI 10.1002/14651858.cd011154.pub2

Verify or expand the search:

Other recruiting trials for Acne Vulgaris

Currently open trials in the same condition.

NCT07341087 — Skin Inflammation in Perimenopause: A Probiotic Intervention Proof of Concept Trial · NA · recruiting
NCT07474883 — Efficacy of 0.5% Topical Timolol Eye Drops in the Treatment of Post-Inflammatory Erythema Following Acne Vulgaris · EARLY_PHASE1 · recruiting
NCT07186413 — A Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne · Phase 3 · recruiting
NCT07056673 — Cold Atmospheric Plasma for Moderate-to-severe Acne Vulgaris Study · NA · recruiting
NCT07102186 — Efficacy and Safety of Adapalene Gel and Hyaluronic Acid Versus Adapalene Gel Alone in Mild to Moderate Acne Vulgaris · Phase 4 · recruiting

Other Cosmetique Active International trials

Trials by the same sponsor.

NCT07239726 — CLINICAL INVESTIGATION TO EVALUATE THE EFFICACY AND SAFETY OF EPILADY PROTOTYPE DEVICE FOLLOWED BY APPLICATION OF A TOPI · NA · not yet recruiting
NCT06590779 — Benefits of a Cosmetic Anti-hair Loss in Males With Hair Loss · NA · not yet recruiting
NCT06516224 — Anti-pigmenting Effect of a Routine of Facial Products in Subjects With Melasma · NA · not yet recruiting
NCT07537595 — Efficacy of Cosmetic Products in Preventing Pigmentation Induced by High Energy Visible Light (HEVL) [400-450nm] · completed
NCT06320314 — Efficacy and Tolerability of Tested Formula After 3 Months in Treatment of Facial Hyperpigmentation of 3 Origins · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00624676 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cosmetique Active International
Last refreshed: 18 September 2011

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00624676.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing